title: Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.
authors.affiliation: Wilhelminen Cancer Research Institute, Wilhelminenspital Wien, Wien, Austria.
authors.forename: H
authors.initials: H
authors.lastname: Ludwig
authors.affiliation: Internal Medicine II, University of Tübingen, Tübingen, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Weisel
authors.affiliation: Department of Hematology, 'Sapienza' University of Rome, Rome, Italy.
authors.forename: M T
authors.initials: MT
authors.lastname: Petrucci
authors.affiliation: Hématologie et Thérapie Cellulaire, Hôpital de La Milétrie, CHU, Inserm CIC 1402, Poitiers, France.
authors.forename: X
authors.initials: X
authors.lastname: Leleu
authors.affiliation: Department of Oncology and Hematology, Niguarda Ca'Granda Hospital, Milano, Italy.
authors.forename: A M
authors.initials: AM
authors.lastname: Cafro
authors.affiliation: Department of Hematology, CHU St Antoine, Paris, France.
authors.forename: L
authors.initials: L
authors.lastname: Garderet
authors.affiliation: Wilhelminen Cancer Research Institute, Wilhelminenspital Wien, Wien, Austria.
authors.forename: C
authors.initials: C
authors.lastname: Leitgeb
authors.affiliation: Department of Hematology, 'Sapienza' University of Rome, Rome, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Foa
authors.affiliation: IIIrd Medical Department, Paracelsus Medical University Salzburg, Salzburg, Austria.
authors.forename: R
authors.initials: R
authors.lastname: Greil
authors.affiliation: Hématologie, CHU de Lille, Inserm U995, Université Lille 2, Lille, France.
authors.forename: I
authors.initials: I
authors.lastname: Yakoub-Agha
authors.affiliation: NOXXON Pharma AG, Berlin, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Zboralski
authors.affiliation: NOXXON Pharma AG, Berlin, Germany.
authors.forename: S
authors.initials: S
authors.lastname: Vauléon
authors.affiliation: NOXXON Pharma AG, Berlin, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Dümmler
authors.affiliation: NOXXON Pharma AG, Berlin, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Beyer
authors.affiliation: NOXXON Pharma AG, Berlin, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Kruschinski
authors.affiliation: NOXXON Pharma AG, Berlin, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Riecke
authors.affiliation: NOXXON Pharma AG, Berlin, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Baumann
authors.affiliation: Internal Medicine I, University of Freiburg, Freiburg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Engelhardt
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069286:Bortezomib / Q000627:therapeutic use*; D054377:Chemokine CXCL12; D003907:Dexamethasone / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism; D009843:Oligoribonucleotides / Q000037:antagonists & inhibitors* / Q000627:therapeutic use*; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism
chemical_list: C515255:CXCL12 protein, human; D054377:Chemokine CXCL12; D009843:Oligoribonucleotides; D000069286:Bortezomib; D003907:Dexamethasone; D046988:Proteasome Endopeptidase Complex